RITALIN-SR
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Mar 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RITALIN-SR is an extended-release oral tablet containing methylphenidate, a central nervous system stimulant approved in 1982. The mechanism of action involves reuptake inhibition of dopamine and norepinephrine, enhancing focus and impulse control. It is primarily indicated for attention-deficit/hyperactivity disorder (ADHD) and narcolepsy.
LOE Approaching
With LOE approaching and 30% competitive pressure, brand teams should expect managed decline and transition to lifecycle extension or generic transition support roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Study to Explore Plasma Levels of CONCERTA, Ritalin-SR and Novo-Methylphenidate ER-C in Healthy Volunteers
Started May 2010
30 enrolled
Pharmacokinetics
Career Relevance
Working on RITALIN-SR offers limited growth opportunities due to its LOE-approaching status, but provides valuable experience in managing mature products, defending market share against generics, and navigating healthcare economics. This role suits professionals seeking to develop lifecycle management, payer relations, and defensive commercial strategy expertise.
Brand Manager
Worked on RITALIN-SR at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.